Competitive Salary: F. Hoffmann-La Roche AG: Impact HealthcareRoche Sequencing is developing ground-breaking next-generation sequencing products that allow scientists/clinicians powerful new aven Santa Clara, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionThe candidate will bring technical expertise into our molecular oncology CLIA laboratory. The laboratory performs high complexity NGS test San Jose, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: Impact HealthcareRoche Sequencing is not only changing science, but we are changing lives. Our software teams are laying the groundwork for the future Ottawa (Region), Ontario (CA)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionThe OMNI Bioinformatics and Immunology departments at Genentech are seeking a highly motivated computational scientist to engage in therap San Francisco, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: As the Head of Assay Bioinformatics, Molecular Lab Applications you will play a key role in setting technical strategy and driving execution for devel United States (US)

Notice NOT-OD-22-216 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-241 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are encouraged to work with their institutions to apply for support under this program eligible to apply. Investigators from categories A and B are particularly encouraged to work with their institutions to apply

Notice NOT-OD-22-214 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-213 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-217 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-215 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-22-059 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models by analyses of relevant pre-clinical and clinical data, and to provide results from optimized models to identify the most promising combination regimens for clinical testing

Funding Opportunity RFA-DA-23-058 from the NIH Guide for Grants and Contracts. As part of the NIH HEAL Initiative, the National Institute on Drug Abuse (NIDA) is releasing a set of interrelated FOAs to create the HEAL Data2Action (HD2A) Program, a coordinated effort to promote the synthesis and real-world application of existing data to improve epidemiology and guide and monitor improvements in service delivery to prevent or treat opioid use disorder (OUD) and pain. Collectively, these projects will improve the quality, timeliness, accessibility and usefulness of data for epidemiology and service delivery in each of the four pillars of the HHS Overdose Prevention Strategy: primary prevention, harm reduction, treatment of opioid use disorder, and recovery support. Separate FOAs have been issued to support multiple HD2A Innovation Projects (RFA-DA-22-051); one HD2A Data Infrastructure Support Center (RFA-DA-22-052); one HD2A Research Adoption Support Center (RFA-DA-22-050); and one HD2A Economics and Modeling Resource Center (RFA-DA-22-049). It is imperative that prospective applicants read all of these related RFAs to better understand the intended purpose and structure of the HD2A Program. This FOA solicits applications for HEAL Data2Action (HD2A) Acceleration Projects. Research Projects will focus on developing data or methods that improves timeliness, quality, accessibility, or usefulness of existing data ecosystems to allow for faster and improved responses and allocation of resources to address the overdose crisis. This FOA invites projects for which preliminary or feasibility data are available, such as from an R21 study or its equivalent. This FOA is a companion to RFA-DA-232-057, which solicits Acceleration and Innovation Project applications for which pilot data are unavailable.

Funding Opportunity RFA-DA-23-057 from the NIH Guide for Grants and Contracts. As part of the NIH HEAL Initiative, the National Institute on Drug Abuse (NIDA) is releasing a set of interrelated RFAs to create the HEAL Data2Action (D2A) Program, a coordinated effort to promote the synthesis and real-world application of existing data to guide and monitor improvements in service delivery to prevent or treat opioid use disorder (OUD) and pain. Collectively, these projects will address gaps in the delivery of evidence-based practices in each of the four pillars of the HHS Overdose Prevention Strategy: primary prevention, harm reduction, treatment of opioid use disorder, and recovery support. Separate FOAs are being issued to support multiple HEAL D2A Innovation Projects (RFA-DA-22-051); one HEAL D2A Data Infrastructure Support Center (RFA-DA-22-052); one HEAL D2A Research Adoption Support Center (RFA-DA-22-050); and one HEAL D2A Economics and Modeling Resource Center (RFA-DA-22-049). It is imperative that prospective applicants read all of these related RFAs to better understand the intended purpose and structure of the HEAL D2A Program.This FOA solicits applications for HEAL D2A Innovation Projects, which are phased awards intended to support local efforts, either within a single system or in cross-sector partnerships, to improve utilization of data to drive prediction and real-time proactive responses to the overdose crisis.

As a member of the bioinformatics team and in this new role you will develop robust analytical pipelines for analysis of a wide range of next generation…
From Cellular Dynamics - Wed, 21 Sep 2022 05:25:32 GMT - View all Madison, WI jobs

Notice NOT-AG-22-038 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-027 from the NIH Guide for Grants and Contracts

Notice NOT-AI-22-064 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-22-029 from the NIH Guide for Grants and Contracts. Reissue RFA-NS-11-009: The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications to participate as a Clinical Coordinating Center in the Network for Excellence in Neuroscience Clinical Trials. This clinical research network will develop and conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network will not be specific to one disease, it will have the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for the Clinical Coordinating Center (CCC). Separate FOAs solicit applications for the Clinical Sites and the Data Coordinating Center.

Funding Opportunity RFA-NS-22-030 from the NIH Guide for Grants and Contracts. Reissue RFA-NS-11-010: The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications to participate as a Data Coordinating Center in the Network for Excellence in Neuroscience Clinical Trials. This clinical research network will develop and conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network will not be specific to one disease, it will have the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for the Data Coordinating Center (DCC). Separate FOAs solicit applications for the Clinical Sites and the Clinical Coordinating Center.